阅读说明：本技术 磷脂酰胆碱经皮吸收制剂 (Transdermal phosphatidylcholine preparation ) 是由 中西博文 于 2018-04-27 设计创作，主要内容包括：本发明提供一种在粘合剂层中含有磷脂酰胆碱的磷脂酰胆碱经皮吸收制剂。本发明涉及的磷脂酰胆碱经皮吸收制剂(1),构成为在支撑体(2)的至少一个面上形成的粘合剂层(3)包含磷脂酰胆碱、粘合成分和亲油性成分,所以能将制剂固定在患处,将所谓与液体等的制剂相比具有更好处理性的剂型作为贴剂,除了上述优点之外,由于磷脂酰胆碱可以稳定地存在于粘合剂层(3)中,所以通过贴附在人体等的皮肤等,利用磷脂酰胆碱的经皮吸收可以使皮下脂肪等局部肥胖溶解,能发挥使脂肪减少等效果,从而可以成为作为含有磷脂酰胆碱的减脂剂起作用的贴剂型的经皮吸收制剂(1)。(The present invention provides a phosphatidylcholine percutaneous absorption preparation containing phosphatidylcholine in an adhesive layer. The phosphatidylcholine percutaneous absorption preparation (1) according to the present invention is configured such that the adhesive layer (3) formed on at least one surface of the support (2) contains phosphatidylcholine, an adhesive component and a lipophilic component, and therefore, the preparation can be fixed to an affected area, and a dosage form having better handling properties than a preparation such as a liquid is used as a patch, and in addition to the above-described advantages, phosphatidylcholine can be stably present in the adhesive layer (3), so that when the preparation is attached to the skin or the like of a human body or the like, local obesity such as subcutaneous fat can be dissolved by percutaneous absorption of phosphatidylcholine, and effects such as fat reduction can be exerted, and thus, the transdermal absorption preparation (1) can be a patch type transdermal absorption preparation that functions as a fat reducing agent containing phosphatidylcholine.)

1. A transdermal preparation comprising a support and an adhesive layer formed on at least one surface of the support,

the binder layer comprises phosphatidylcholine, a binding component, and a lipophilic component.

2. The percutaneous absorption preparation according to claim 1,

the adhesive component is a styrenic based thermoplastic elastomer.

3. The percutaneous absorption preparation according to claim 1 or 2,

further comprises carnitine.

4. The percutaneous absorption preparation according to any one of claims 1 to 3,

the content of phosphatidylcholine is 2.5-8.0 mass% relative to the entire adhesive layer.

5. The percutaneous absorption preparation according to any one of claims 1 to 4,

the lipophilic component comprises mineral oil.

6. The percutaneous absorption preparation according to any one of claims 1 to 5,

further comprising a polyolefin having a branched structure.

7. The percutaneous absorption preparation according to claim 6,

the polyolefin with a branched structure is a hydrogenated C6-14 olefin polymer.

Technical Field

The present invention relates to a phosphatidylcholine percutaneous absorption preparation. More specifically, the present invention relates to a patch-type transdermal absorption preparation comprising phosphatidylcholine in an adhesive layer.

Background

Phosphatidylcholine is a main component of soybean lecithin obtained from oil extracted from soybean seeds, and is used as a surfactant (emulsifier, etc.), a skin conditioner, etc. in cosmetics, pharmaceuticals, etc. The phosphatidylcholine including both hydrophilic and lipophilic ones can penetrate fat cells, and phosphatidic acid such as phosphatidylcholine participates in activation of a fatty acid release pathway that reduces local obesity such as subcutaneous fat, and therefore, the effect of dissolving subcutaneous fat can be expected to be exerted.

As a means for reducing obesity including subcutaneous fat accumulation and excess fat (having a fat layer) in obesity, for example, a method of directly injecting a composition for removing subcutaneous fat accumulation subcutaneously is employed, and a phosphatidylcholine preparation or the like is used as the composition (for example, see patent document 1). However, this subcutaneous injection of phosphatidylcholine preparations is accompanied by pain during the treatment. Since this is problematic in terms of safety and the like, development of a percutaneous absorption type preparation (percutaneous absorption preparation, also referred to as a transdermal preparation) that can achieve self-administration without direct subcutaneous injection is desired. Thus, a transdermal composition containing natural phosphatidylcholine, L-carnitine, propylene glycol, glycerol, and water, but not including a lipophilic base, is provided (for example, see patent document 2).

Disclosure of Invention

Problems to be solved by the invention

In addition, it is desired to provide a percutaneously absorbable preparation which contains phosphatidylcholine in an adhesive layer and which is made into a patch. The transdermal drug delivery system in which the adhesive layer contains phosphatidylcholine and the dosage form is a patch can provide a transdermal drug delivery system of a type that is not applied to the skin or the like, and the transdermal drug delivery system can be attached to an affected area in consideration of fat reduction or the like to fix the drug to the affected area or the like, and has an advantage that the dosage form is a patch, and in addition, has a better handling property than a liquid or gel preparation. However, in the configuration of the preparation provided so far such as the configuration disclosed in the above-mentioned patent document 2, it is difficult to make the dosage form a patch.

The present invention has been made in view of the above problems, and provides a transdermal phosphatidylcholine absorption preparation in the form of a patch containing phosphatidylcholine in an adhesive layer.

Means for solving the problems

In order to solve the above problems, the present invention provides a transdermal drug delivery system comprising a support and an adhesive layer formed on at least one surface of the support, wherein the adhesive layer contains phosphatidylcholine, an adhesive component and a lipophilic component.

The transdermal preparation according to the present invention is characterized in that the adhesive component is a styrene-based thermoplastic elastomer in the present invention.

The transdermal preparation according to the present invention is characterized in that carnitine is further contained in the present invention.

The transdermal preparation according to the present invention is characterized in that, in the present invention, the content of phosphatidylcholine is 2.5 to 8.0 mass% with respect to the entire adhesive layer.

The transdermal absorption preparation according to the present invention is characterized in that the lipophilic component contains mineral oil.

The transdermal preparation according to the present invention is characterized in that the transdermal preparation further contains a polyolefin having a branched structure.

The transdermal patch of the present invention is characterized in that, in the present invention, the polyolefin having a branched structure is a hydrogenated C6-14 olefin polymer.

Effects of the invention

The present invention relates to a phosphatidylcholine transdermal absorption preparation, which is configured such that a binder layer formed on at least one surface of a support contains phosphatidylcholine, a binder component, and a lipophilic component. This makes it possible to fix the preparation to the affected part, and has the advantages of better handling properties than liquid preparations and the like, and the preparation is a patch, and in addition, phosphatidylcholine is stably present in the adhesive layer, and therefore, by being applied to the skin of the human body or the like, the transdermal absorption of phosphatidylcholine is utilized to dissolve local obesity such as subcutaneous fat, and the like, thereby exerting the effect of reducing fat, and the like, and a patch-type transdermal absorption preparation functioning as a fat-reducing agent containing phosphatidylcholine can be produced.

Drawings

Fig. 1 is a front view showing one embodiment of a transdermal absorption preparation according to the present invention.

Fig. 2 is a sectional view taken along line a-a of fig. 1.

Detailed Description

(I) Constitution of percutaneous absorption preparation 1

Hereinafter, one embodiment of the phosphatidylcholine transdermal absorption preparation 1 according to the present invention will be described. Fig. 1 is a front view showing one embodiment of a transdermal absorption preparation 1 according to the present invention, and fig. 2 is a sectional view taken along line a-a of fig. 1. In the figure, 1 denotes a phosphatidylcholine percutaneous absorption preparation (percutaneous absorption preparation), 2 denotes a support, 3 denotes an adhesive layer, 4 denotes a release sheet, and 41 denotes a cut.

The phosphatidylcholine transdermal absorption preparation (transdermal absorption preparation) 1 according to the present invention is a transdermal absorption preparation 1 having a support 2 and an adhesive layer 3 formed on at least one surface of the support 2, and basically has a structure in which the reagent layer 3 contains phosphatidylcholine, an adhesive component, and a lipophilic component. Fig. 1 and 2 show a configuration in which an adhesive layer 3 is formed on one surface of a support 2 and a release sheet 4 is attached to the surface of the adhesive layer 3, as an example of the configuration of the transdermally-absorbable preparation 1.

(II) support 2

In the present invention, the support 2 is not particularly limited as long as it can be used as a support generally used for the support application of the patch of the transdermal absorption preparation 1, and examples thereof include a stretchable or non-stretchable woven fabric or nonwoven fabric containing polyethylene, polypropylene, or the like, a polyolefin such as polyethylene, polypropylene, or the like, a polyester such as polyethylene terephthalate (PET), polyethylene naphthalate (PEN), or the like, a film or sheet of an ethylene-vinyl acetate copolymer, vinyl chloride, or the like (in the present invention, "film" and "sheet" are synonymous and the same applies hereinafter), and a foamable sheet such as urethane, polyurethane, or the like (may be referred to as "sheet" above). The above-mentioned substances may be used alone in 1 kind, or may be used in combination in 2 or more kinds (mixed or laminated). In order to prevent static electricity from accumulating on the support 2, an antistatic agent or the like may be contained in a sheet-like material such as the woven fabric or the nonwoven fabric constituting the support 2.

The thickness of the support 2 in the transdermal preparation 1 is, for example, preferably 200 to 280 μm, and particularly preferably about 240 to 260 μm, but is not particularly limited to this range.

As shown in fig. 1 and 2, the transdermal preparation 1 of the present invention may be configured such that the pressure-sensitive adhesive layer 3 is sandwiched between the support 2 and the release sheet 4. The release sheet 4 may be a release sheet 4 generally used in the field of adhesive patches. Examples of the release sheet 4 include polyolefins such as polyethylene and polypropylene, polyesters such as polyethylene terephthalate (PET) and polyethylene naphthalate (PEN), resin sheets such as polystyrene, cellophane, aluminum sheets, foamed polyethylene sheets and foamed polypropylene sheets, and laminates of 2 or more of the above. Further, a sheet obtained by subjecting these to silicone processing, a sheet obtained by subjecting them to fluororesin processing, a sheet obtained by subjecting them to embossing processing, hydrophilic processing, hydrophobic processing, or the like can be used.

The thickness of the release sheet 4 is preferably 80 to 120 μm, and particularly preferably 90 to 110 μm, for example, but is not particularly limited to this range.

In order to facilitate the peeling from the pressure-sensitive adhesive layer 3, it is preferable to form a cut (slit) 41 in the release sheet 4. In the configuration shown in fig. 1, two curved cuts 41 are formed and the release sheet 4 is divided into three embodiments.

(III) adhesive layer 3

The adhesive layer 3 contains phosphatidylcholine, an adhesive component and a lipophilic component. Phosphatidylcholine (Phosphatidablcholine) is a general name for phospholipids mostly having a structure in which choline forms a phosphate ester bond as a hydrophilic portion of glycerophospholipids and 2 fatty acids of the glycerol backbone form an ester bond as a hydrophobic portion. Phosphatidylcholine is a main component of soybean lecithin obtained from soybean seed extract oil, and is involved in activation of a fatty acid release pathway that reduces local obesity such as subcutaneous fat by permeating fat cells, thereby exhibiting a dissolving effect of subcutaneous fat. It should be noted that phosphatidylcholine has different phospholipid names depending on the selection of 2 fatty acids, and is called dipalmitoylphosphatidylcholine when 2 palmitic acids are selected as the fatty acids; when two linoleic acids are selected as fatty acids, it is called DL phosphatidylcholine, when 2 palmitic acids are selected as fatty acids, it is called dipalmitoyl phosphatidylcholine; when palmitic acid and oleic acid are chosen as the fatty acids, they are referred to as PO phosphatidylcholine.

Examples of the phosphatidylcholine include conventionally known egg yolk phosphatidylcholine, soybean phosphatidylcholine, egg yolk lysophosphatidylcholine, soybean lysophosphatidylcholine, hydrogenated egg yolk phosphatidylcholine, hydrogenated soybean phosphatidylcholine, hydrogenated egg yolk lysophosphatidylcholine, hydrogenated soybean lysophosphatidylcholine, and the like, and 1 kind of these can be used alone, or 2 or more kinds can be used in combination.

The content of phosphatidylcholine in the pressure-sensitive adhesive layer 3 is preferably 1.0 to 9.0 parts by mass relative to the entire pressure-sensitive adhesive layer 3 (the total mass of the pressure-sensitive adhesive layer 3 is 100% by mass; the same applies hereinafter). By setting the content of phosphatidylcholine within this range, the effect of reducing local obesity such as subcutaneous fat by transdermal absorption of phosphatidylcholine can be effectively exhibited as a transdermal absorption preparation in a patch form. The content of phosphatidylcholine is particularly preferably 2.5 to 8.0 mass% with respect to the entire adhesive layer 3.

Carnitine may be added to phosphatidylcholine. The presence of carnitine improves the stability of phosphatidylcholine in the adhesive layer 3, and the effect of containing phosphatidylcholine can be more effectively exhibited. Examples of carnitine include L-carnitine, DL-carnitine, and acetyl-L-carnitine, and 1 of these may be used alone or 2 or more may be used in combination. In the present invention, L-carnitine is preferably used. Further, as carnitine, inorganic salts such as inner salt, hydrochloride and sodium salt, organic acid salts such as tartrate, oxalate and fumarate, and the like can be used.

The amount of carnitine added is preferably 8.5 to 12.0 parts by mass, and more preferably 9.0 to 10.5 parts by mass, based on 100 parts by mass of phosphatidylcholine.

Next, as an adhesive component forming the adhesive layer 3, for example, a thermoplastic elastomer is preferably used. Here, the "thermoplastic elastomer" is a generic term for elastomers exhibiting thermoplastic properties such as softening by heating and exhibiting fluidity while returning to a rubber-like elastomer by cooling. Examples of such thermoplastic elastomers include styrene-based, urethane-based, acrylic, and olefin-based thermoplastic elastomers. In the present invention, it is preferable to use a styrene-based thermoplastic elastomer (including a hydrogenated styrene-based thermoplastic elastomer) which can stably cause phosphatidylcholine to be present in the adhesive layer 3 and has sufficient skin adhesiveness and low skin irritation, and it is particularly preferable to use a styrene-based copolymer (including a hydrogenated copolymer) such as a styrene-based block copolymer.

Specific examples of the styrenic block copolymer (including hydrogenated copolymers, the same applies hereinafter) of the thermoplastic elastomer include a styrene-butadiene block copolymer, a hydrogenated styrene-butadiene block copolymer, a styrene-butadiene-styrene block copolymer, a hydrogenated styrene-butadiene-styrene block copolymer, a styrene-isoprene block copolymer, a hydrogenated styrene-isoprene block copolymer, a styrene-isoprene-styrene block copolymer, and a hydrogenated styrene-isoprene-styrene block copolymer. Further, there may be mentioned a styrene-ethylene/butylene block copolymer, a styrene-ethylene/butylene-styrene block copolymer, a styrene-ethylene/propylene-styrene block copolymer, a styrene-isobutylene-styrene block copolymer and the like, and hydrogenated block copolymers thereof and the like. These styrene block copolymers may be used alone in 1 kind, or may be used in combination in 2 or more kinds.

In the above, the expression "ethylene/butene" refers to a copolymer block of ethylene and butene, and the expression "ethylene/propylene" refers to a copolymer block of ethylene and propylene.

Among the above-mentioned styrenic block copolymers, at least one selected from the group consisting of a styrene-butadiene block copolymer, a hydrogenated styrene-butadiene block copolymer, a styrene-isoprene block copolymer, a hydrogenated styrene-isoprene block copolymer, a styrene-isoprene-styrene block copolymer, and a hydrogenated styrene-isoprene-styrene block copolymer is preferably used from the viewpoint of having good skin adhesiveness and low skin irritation, and being easily available and easy to handle.

The styrene-butadiene block copolymer (including a hydrogenated copolymer) preferably contains a styrene component in an amount of 5 to 55% by mass, particularly preferably 10 to 50% by mass. Further, the weight average molecular weight (hereinafter, the same as) measured by gel filtration chromatography or the like is preferably 10000 to 5500000, and particularly preferably 15000 to 500000.

The styrene-isoprene block copolymer (including a hydrogenated copolymer) preferably contains a styrene component in an amount of 5 to 55 mass%, particularly preferably 10 to 50 mass%. The weight average molecular weight is preferably 10000 to 5500000, and more preferably 15000 to 500000.

Further, as the styrene-isoprene-styrene block copolymer (including hydrogenated copolymer), the content of the styrene component in the copolymer is preferably 5 to 65% by mass, and particularly preferably 10 to 60% by mass. The weight average molecular weight is preferably 18000 to 5500000, and particularly preferably 20000 to 500000.

The content of the adhesive component such as a thermoplastic elastomer in the adhesive layer 3 is preferably 20.0 to 35.0 mass% with respect to the entire adhesive layer 3. If the content of the pressure-sensitive adhesive component is less than 20.0 mass%, the shape of the pressure-sensitive adhesive layer 3 may be difficult to maintain, and if it exceeds 35.0 mass%, the pressure-sensitive adhesive property to the skin may be insufficient, which is not preferable. The content of the adhesive component such as a thermoplastic elastomer in the adhesive layer 3 is particularly preferably 25.0 to 30.0 mass% with respect to the entire adhesive layer 3.

It is preferable to blend a polyolefin having a branched structure for the purpose of improving the hardness and transparency of the pressure-sensitive adhesive layer 3, improving the feeling of use, and improving the mixing and dispersion of the components of the pressure-sensitive adhesive layer 3. Examples of such polyolefins include hydrogenated C6-14 olefin polymers, polybutene, hydrogenated polyisobutene, (C7, 8) isoparaffins, (C8, 9) isoparaffins, (C9-11) isoparaffins, (C10-13) isoparaffins, (C11, 12) isoparaffins, (C11-13) isoparaffins, (C13, 14) isoparaffins, (C13-16) isoparaffins, (C18-70) isoparaffins, and other isoparaffins, olefin oligomers, hydrogenated polydecene, and the like. Among them, hydrogenated C6-14 olefin polymers, polybutene and hydrogenated polyisobutene are particularly preferable from the viewpoint of the transparency, adhesiveness and other usability of the pressure-sensitive adhesive layer 3. These can be used alone in 1, also can be combined with more than 2.

The content of the polyolefin having a branched structure in the adhesive layer 3 is preferably 2.0 to 15.0% by mass, and particularly preferably 4.0 to 10.0% by mass, based on the entire adhesive layer 3.

The lipophilic component is an effective component for forming the phosphatidylcholine and the binder component into the binder layer 3 in the present invention, and examples thereof include vegetable oils such as olive oil (olive oil), orange oil (orange oil), and mineral oil, animal oils, and mineral oils. By containing mineral oil in these components and the lipophilic component described below, the effect of percutaneous absorption of phosphatidylcholine can be more effectively exerted.

Further, examples of the lipophilic component include fatty acids such as palmitic acid, oleic acid, and stearic acid; vegetable oils such as avocado oil, linseed oil, almond oil, perilla oil, torreya oil, rapeseed oil, olive oil, corn oil, castor oil, safflower oil, sunflower seed oil, cottonseed oil, jojoba oil, macadamia nut oil, wheat germ oil, soybean oil, peanut oil, coconut oil, palm kernel oil, camellia oil, evening primrose oil and the like; animal oils such as mink oil, fish oil, lard, and beef tallow; hydrocarbons such as liquid paraffin, squalene, squalane, polybutene, and hydrogenated polyisobutene; diisobutyl adipate, 2-hexyldecyl adipate, di-2-heptylundecyl adipate, N-alkylethyleneglycol monoisostearate, isocetyl isostearate, trimethylolpropane triisostearate, cetyl 2-ethylhexanoate, ethylene glycol di-2-ethylhexanoate, neopentyl glycol di-2-ethylhexanoate, glycerol tri-2-ethylhexanoate, trimethylolpropane tri-2-ethylhexanoate, pentaerythritol tetra-2-ethylhexanoate, cetyl octanoate, octyl dodecyl gum, oleyl oleate, octyl dodecyl oleate, decyl oleate, neopentyl glycol didecanoate, triethyl citrate, 2-ethylhexyl succinate, pentyl acetate, ethyl acetate, butyl acetate, isocetyl stearate, Esters such as butyl stearate, diisopropyl sebacate, di-2-ethylhexyl sebacate, cetyl lactate, myristyl lactate, isopropyl palmitate, 2-ethylhexyl palmitate, 2-hexyldecyl palmitate, 2-heptylundecyl palmitate, cholesterol 12-hydroxystearate, dipentaerythritol fatty acid esters, isopropyl myristate, 2-octyldodecyl myristate, 2-hexyldecyl myristate, myristyl myristate, hexyldecyl dimethyloctanoate, ethyl laurate, hexyl laurate, 2-octyldodecyl N-lauroyl-L-glutamate, and diisostearyl malate; silicones such as dimethylpolysiloxane, methylphenylpolysiloxane, methylhydrogenpolysiloxane, octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane, tetramethyltetrahydrocyclotetrasiloxane and fluorine-modified polysiloxane; fluorine-containing oils such as perfluorodecane, perfluorooctane and perfluoropolyether. The lipophilic components mentioned above may be used alone in 1 kind, or in combination of 2 or more kinds.

The content of the lipophilic component in the pressure-sensitive adhesive layer 3 is preferably 30.0 to 85.0% by mass, more preferably 40.0 to 75.0% by mass, and particularly preferably 40 to 60% by mass, based on the entire pressure-sensitive adhesive layer 3.

In the pressure-sensitive adhesive layer 3 having the above-described configuration, as an optional component, an antioxidant, a plasticizer, a filler, a drug dissolution aid, an antibacterial agent, a skin irritation reducing agent, an excipient, and the like may be appropriately blended as necessary within a range not affecting the object and the effect of the present invention.

The antioxidant is not particularly limited, and examples thereof include ascorbic acid derivatives such as ascorbyl palmitate and ascorbyl tetraisopalmitate, chelating agents such as sodium edetate, sodium sulfite, tocopherols and tocopherol derivatives such as butyl hydroxyanisole, butyl hydroxytoluene and tocopherol, and quinoline derivatives such as hydroxyquinoline sulfate.

The plasticizer is not particularly limited, and examples thereof include glycols such as ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, polyethylene glycol, and polypropylene glycol; oils and fats such as olive oil, castor oil, squalene, lanolin, etc.; hydrocarbons such as liquid paraffin; fatty acid esters such as diisopropyl adipate, diisobutyl adipate, benzyl benzoate, cetyl 2-ethylhexanoate, oleyl oleate, decyl oleate, benzyl acetate, diisopropyl sebacate, diethyl sebacate, sorbitol trioleate, sorbitol tristearate, cetyl palmitate, octyldodecyl myristate, cetyl myristate, myristyl myristate, isopropyl myristate, and the like, and 1 kind of these may be used alone or 2 or more kinds may be used in combination.

The filler is not particularly limited, and examples thereof include kaolin, bentonite, and titanium dioxide. The drug dissolution aid is not particularly limited, and examples thereof include cyclodextrins such as α -cyclodextrin, β -cyclodextrin, and γ -cyclodextrin (which can also be used as an excipient described later). The antibacterial agent is not particularly limited, and examples thereof include benzalkonium chloride, benzoic acid, and methylparaben. The skin irritation reducing agent is not particularly limited, and examples thereof include silicic anhydride. The excipient is not particularly limited, and examples thereof include cyclodextrin, lactose, cellulose-based powders, and the like (excipients such as cyclodextrin are usually used after mixing with carnitine and the like in advance).

In order to obtain the transdermal absorption preparation 1 of the present invention, for example, a coating solution for forming the pressure-sensitive adhesive layer 3 is prepared by mixing and dispersing a lipophilic component with a binder component such as phosphatidylcholine or a thermoplastic elastomer and a component added as necessary, respectively, among the components constituting the pressure-sensitive adhesive layer 3, and mixing or dispersing the mixture in a solvent such as acetone, ethyl acetate, or toluene as necessary. Then, the obtained coating liquid is applied to the surface of the support 2 on which the pressure-sensitive adhesive layer 3 is formed, and then dried (the solvent is scattered when mixed with the solvent, for example). The thickness of the adhesive layer 3 is preferably about 150 to 300 μm after drying.

In the case of using the release sheet 4, the release sheet 4 may be pressure-bonded to the pressure-sensitive adhesive layer 3 after being applied to the support 2, and the pressure-sensitive adhesive layer 3 may be laminated with the release sheet 4 interposed between the support 2. Alternatively, the coating liquid of the pressure-sensitive adhesive layer 3 may be applied to the release layer 4, dried to scatter the solvent, the pressure-sensitive adhesive layer 3 may be formed on the surface of the release sheet 4, and then the support 2 may be bonded to the pressure-sensitive adhesive layer 3 by pressure bonding.

The coating liquid for forming the pressure-sensitive adhesive layer 3 can be applied using a conventionally known coater such as a roll coater, die coater, gravure roll coater, reverse roll coater, kiss roll coater, dip roll coater, bar coater, knife coater, or spray coater. The coating liquid is preferably dried at a temperature of, for example, about 40 to 160 ℃.

As described above, the phosphatidylcholine transdermal absorption preparation 1 according to the present invention is configured such that the pressure-sensitive adhesive layer 3 formed on at least one surface of the support 2 contains phosphatidylcholine, a pressure-sensitive adhesive component, and a lipophilic component. Thus, there is an advantage that a dosage form which can fix the preparation to an affected part and has better handling properties than a liquid preparation or the like can be provided as a patch, and in addition, phosphatidylcholine can be stably present in the adhesive layer 3, and therefore, by being attached to the skin or the like of a human body or the like, the transdermal absorption of phosphatidylcholine is utilized to dissolve local obesity such as subcutaneous fat and the like, and the effect such as fat reduction can be exerted, and thus the patch-type transdermal absorption preparation 1 which functions as a fat reduction agent containing phosphatidylcholine can be obtained.

The transdermal phosphatidylcholine absorption preparation 1 of the present invention employs a patch using the adhesive layer 3 containing a lipophilic component instead of a hydrophilic component, and thereby, phosphatidylcholine as a drug is absorbed from the skin through the skin well, but the permeation mechanism is considered as follows.

Namely, the reason is presumed as follows: by attaching the transdermal absorption preparation 1 as a patch to the skin, phosphatidylcholine sequentially permeates from the skin surface (sebaceous membrane) to the deep part of the skin (skin) by the concentration gradient of the skin. In addition, in addition to the support 2, the evaporation of water in the stratum corneum of the skin is suppressed by a sealing effect (ODT: sealing Therapy) effect) based on a lipophilic component or the like, the stratum corneum swells and a polymer such as a thermoplastic elastomer as an adhesive component softens (plasticization of the polymer), whereby the passage of phosphatidylcholine into the skin becomes good, and the phosphatidylcholine is absorbed into the skin while the permeability into the skin is enhanced.

Further, in the mechanism of percutaneous absorption, low-molecular components permeate the stratum corneum, but unlike high-molecular components, cells on the inner walls of pores already present on the skin surface, such as sweat glands and hair follicles, are the main permeation pathway. The low-molecular component diffuses in the inside of the lipophilic base (adhesive layer 3) and the stratum corneum, spreads in the epidermis, diffuses in the dermis, is absorbed into the cells and capillaries, and the high-molecular component diffuses in the lipophilic base and the pores, spreads to the cells on the inner wall of the pores, and reaches the dermis without passing through the stratum corneum. In the present invention, it is considered that the stratum corneum swells by the sealing effect of the lipophilic component or the like, thereby promoting diffusion in the pores and improving the permeation efficiency of the active ingredient.

The transdermal preparation 1 according to the present invention is expected to have an effect of dissolving local obesity such as subcutaneous fat by transdermal absorption of phosphatidylcholine to reduce fat and the like, and is used so as to be attached to (the skin of) an affected part in which subcutaneous fat in the human body or the like is to be reduced. The frequency of application of the transdermally-absorbable preparation 1 may be appropriately determined depending on the content of phosphatidylcholine or the like in the pressure-sensitive adhesive layer 3, the type and content of other constituent components, and the like, but it is considered that the effect can be exerted efficiently by application approximately 3 to 6 times per week (not particularly limited to this range).

The embodiment described above is one embodiment of the present invention, and the present invention is not limited to the above embodiment, and it goes without saying that modifications and improvements within a range in which the object and the effect can be achieved with the configuration of the present invention are included in the content of the present invention. It is to be understood that the specific configuration, shape, and the like in carrying out the present invention may be other configurations, shapes, and the like within a range in which the object and the effect of the present invention can be achieved. The present invention is not limited to the above embodiments, and modifications and improvements within a range that can achieve the object of the present invention are included in the present invention.

For example, in the above-described embodiment, as the configuration of the transdermal absorption preparation 1, as shown in fig. 1, an embodiment in which two curved cuts 41 are formed in the release sheet 4 is described, but the shape of the cuts 41 may be any shape, and the cuts 41 may not be formed. In addition to this, only the support 2 and the adhesive layer 3 may be used without using the release sheet 41.

In the above-described embodiment, a configuration in which the pressure-sensitive adhesive layer 3 is formed on one surface of the support 2 and the release sheet 4 is attached to the surface of the pressure-sensitive adhesive layer 3 is described as an example of the configuration of the transdermally-absorbable preparation 1 with reference to fig. 2 and 3. However, the pressure-sensitive adhesive layer 3 may be formed on both sides of the support 2, and the release sheet 4 may be attached to the surface of the pressure-sensitive adhesive layer 3 as necessary.

In the above-described embodiment, the shape of the transdermally-absorbable preparation 1 has been described by taking a substantially rectangular shape with four rounded corners as shown in fig. 1 as an example, but the shape of the transdermally-absorbable preparation 1 may be any shape, and any shape such as a polygon such as a triangle, a quadrangle, or a pentagon, a circle, an ellipse, or a geometric shape may be used. The size of the transdermal preparation 1 may be set to any size, and may be appropriately determined depending on the application site and the like. In the case of a substantially rectangular shape (quadrangle) as shown in fig. 1, for example, one side (before rounding in the case of rounding the four corners) may be set to, for example, about 50 to 200mm, but is not particularly limited to this range.

The specific configuration, shape, and the like in carrying out the present invention may be other configurations and the like within a range in which the object of the present invention can be achieved.